A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Dec 2016
At a glance
- Drugs GEN 003 (Primary)
- Indications Herpes simplex virus type 2 infections
- Focus Therapeutic Use
- Sponsors Genocea Biosciences
- 19 Dec 2016 Planned End Date changed from 1 Nov 2018 to 1 Dec 2018.
- 19 Dec 2016 Planned primary completion date changed from 1 Nov 2018 to 1 Dec 2018.
- 19 Dec 2016 Status changed from recruiting to active, no longer recruiting.